Healthcare -
Biotechnology - NASDAQ - US
$ 21.55
-2.95 %
$ 737 M
Market Cap
-5.86
P/E
1. INTRINSIC VALUE
Balance Sheet
ArriVent BioPharma, Inc. Common Stock
| Current Assets | 227 M |
| Cash & Short-Term Investments | 219 M |
| Receivables | 500 K |
| Other Current Assets | 7.62 M |
| Non-Current Assets | 48 M |
| Long-Term Investments | 47.7 M |
| PP&E | 154 K |
| Other Non-Current Assets | 126 K |
| Current Liabilities | 17.3 M |
| Accounts Payable | 3.78 M |
| Short-Term Debt | 324 K |
| Other Current Liabilities | 13.2 M |
| Non-Current Liabilities | 14 K |
| Long-Term Debt | 14 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
ArriVent BioPharma, Inc. Common Stock
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 94.3 M |
| Operating Income | -94.3 M |
| Other Expenses | -13.8 M |
| Net Income | -80.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ArriVent BioPharma, Inc. Common Stock
| Net Income | -80.5 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 3.21 M |
| Change in Working Capital | 7.07 M |
| Others | 7.82 M |
| Free Cash Flow | -70.2 M |
Wall Street Analysts Price Targets
ArriVent BioPharma, Inc. Common Stock
Wall Street analysts predict an average 1-year price target for AVBP of $33.8 , with forecasts ranging from
a
low of
$30 to a high of $36 .
AVBP Lowest Price Target
Wall Street Target
30 USD
39.21%
AVBP Average Price Target
Wall Street Target
33.8 USD
56.61%
AVBP Highest Price Target
Wall Street Target
36 USD
67.05%
4. DIVIDEND
ANALYSIS
AVBP does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ArriVent BioPharma, Inc. Common Stock
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study in first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC) is projected to be in early 2026.
globenewswire.com
- 1 day ago
New Strong Sell Stocks for July 21st
CDZI, AVBP and ACCO have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2025.
zacks.com
- 2 days ago
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
benzinga.com
- 2 weeks ago
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.
globenewswire.com
- 3 weeks ago
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, ArriVent expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of common stock and shares of common stock underlying pre-funded warrants on the same terms and conditions. All of the securities are being offered by ArriVent.
globenewswire.com
- 3 weeks ago
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients
globenewswire.com
- 4 weeks ago
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) on June 23, 2025 at 8:00 am ET.
globenewswire.com
- 1 month ago
ArriVent BioPharma Reports First Quarter 2025 Financial Results
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent Company progress.
globenewswire.com
- 2 months ago
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D.
globenewswire.com
- 2 months ago
ArriVent BioPharma Reports Full Year 2024 Financial Results
NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2024, and highlighted recent Company progress.
globenewswire.com
- 4 months ago
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) that can target several gastrointestinal (GI) cancers. Under the terms of the agreement, ArriVent obtains the exclusive rights to develop and commercialize MRG007 worldwide outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan.
globenewswire.com
- 6 months ago
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
marketbeat.com
- 8 months ago
8. Profile
Summary
ArriVent BioPharma, Inc. Common Stock AVBP
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 737 M
Dividend Yield
0.00%
Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Contact
18 Campus Boulevard, Newtown Square, 19073
https://www.arrivent.com
IPO
Date
Jan. 26, 2024
Employees
52
Officers
Dr. Stuart Lutzker M.D., Ph.D.
Co-Founder, President of Research & Development and Director
Dr. Zhengbin Yao Ph.D.
Co-Founder, Chairman, President & Chief Executive Officer
Ms. Yang Wang Ph.D.
Chief Technology Officer
Ms. Robin LaChapelle M.A.
Co-Founder & Chief Operating Officer
Mr. Winston Kung M.B.A.
Chief Financial Officer & Treasurer
Dr. James Paul Kastenmayer J.D., Ph.D.
General Counsel & Secretary
Ms. Meghna Chowdary
Senior Vice President of Commercial Strategy